Skip to main content
Premium Trial:

Request an Annual Quote

RBM Nets $25M in VC Cash; Funds Will Help Finance M&A, Grow Dx Service

NEW YORK (GenomeWeb News) — Multiplexed biomarker testing lab Rules-Based Medicine has raised $25 million in a Series A round of private equity financing, the company said yesterday.
The Austin, Tex.-based shop said it plans to use the cash for aggressive growth in the services business, to fund development of diagnostics services and kits, to shore up its balance sheet, to repay debts, and to make acquisitions and investments in the biomarker and medical diagnostics fields.
In addition, RBM will use $12.5 million of the financing to pay Luminex under the terms of a lawsuit settlement disclosed earlier this week.  
The financing was led by Equity Group Investments, and included contributions from Cross Creek Capital and Stephens Capital Partners.
As part of the funding, Matt Zell, managing director of EGI, has joined RBM's board of directors.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.